Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1180

1.

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.

Wallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS.

BMC Med. 2019 Jun 17;17(1):117. doi: 10.1186/s12916-019-1344-3.

2.

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.

Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA.

Mod Pathol. 2019 Jun 12. doi: 10.1038/s41379-019-0303-z. [Epub ahead of print]

PMID:
31190001
3.

Non-Inferiority Designed Cardiovascular Trials in Highest-Impact Journals: Main Findings, Methodological Quality and Time Trends.

Bikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, Kaul S, Stone GW, Ross JS, Krumholz HM.

Circulation. 2019 Jun 10. doi: 10.1161/CIRCULATIONAHA.119.040214. [Epub ahead of print]

PMID:
31177811
4.

Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio JA, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich AC, Ali SM, Chung JH, Reddy P, Miller VA, Schrock AB, Gay LM, Ross JS, Jacob JM.

Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30149-X. doi: 10.1016/j.euf.2019.05.012. [Epub ahead of print]

PMID:
31147264
5.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.

Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC, Baker WL.

J Am Geriatr Soc. 2019 May 29. doi: 10.1111/jgs.15966. [Epub ahead of print]

PMID:
31140587
6.

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.

Skydel JJ, Luxkaranayagam AT, Dhruva SS, Ross JS, Wallach JD.

JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.

7.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]

PMID:
31040255
8.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.

Ann Oncol. 2019 Apr 30. pii: mdz134. doi: 10.1093/annonc/mdz134. [Epub ahead of print]

PMID:
31038663
9.

Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids.

Fleischman W, Agrawal S, Gross CP, Ross JS.

J Gen Intern Med. 2019 Apr 22. doi: 10.1007/s11606-019-04897-9. [Epub ahead of print] No abstract available.

PMID:
31011967
10.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

PMID:
31011206
11.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults [Internet].

Sobieraj DM, Baker WL, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Mar.

12.

Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study.

Weerahandi H, Li L, Bao H, Herrin J, Dharmarajan K, Ross JS, Kim KL, Jones S, Horwitz LI.

J Am Med Dir Assoc. 2019 Apr;20(4):432-437. doi: 10.1016/j.jamda.2019.01.135.

PMID:
30954133
13.

Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition.

Venkatesh AK, Chou SC, Li SX, Choi J, Ross JS, D'Onofrio G, Krumholz HM, Dharmarajan K.

JAMA Intern Med. 2019 Apr 1. doi: 10.1001/jamainternmed.2019.0037. [Epub ahead of print]

PMID:
30933243
14.

Kept in the dark: Scotland rejects "sunshine" legislation.

Ross JS.

BMJ. 2019 Mar 29;364:l1379. doi: 10.1136/bmj.l1379. No abstract available.

PMID:
30926587
15.

Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing.

Fleischman W, Auth D, Shah ND, Agrawal S, Ross JS.

JAMA Netw Open. 2019 Mar 1;2(3):e191340. doi: 10.1001/jamanetworkopen.2019.1340.

16.

Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation.

Jackevicius CA, An J, Ko DT, Ross JS, Angraal S, Wallach JD, Koh M, Song J, Krumholz HM.

BMJ Open. 2019 Mar 23;9(3):e025936. doi: 10.1136/bmjopen-2018-025936.

17.

U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015.

Vijay A, Rhee TG, Ross JS.

Prev Med. 2019 Jun;123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.

PMID:
30894321
18.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N.

Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.

19.

Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials.

Ross JS, Wee CC.

JAMA Intern Med. 2019 Mar 4. doi: 10.1001/jamainternmed.2018.8019. [Epub ahead of print] No abstract available.

PMID:
30830205
20.

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.

Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM.

Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22.

PMID:
30796031
21.

On the Need for (Only) High-Quality Clinical Practice Guidelines.

Incze M, Ross JS.

JAMA Intern Med. 2019 Feb 18. doi: 10.1001/jamainternmed.2018.7471. [Epub ahead of print] No abstract available.

PMID:
30776052
22.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.

Head Neck. 2019 Jun;41(6):1928-1934. doi: 10.1002/hed.25634. Epub 2019 Feb 13.

PMID:
30758123
23.

Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.

Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, Lipska KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND.

J Clin Endocrinol Metab. 2019 Jun 1;104(6):2305-2314. doi: 10.1210/jc.2018-02197.

PMID:
30690529
24.

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

Boussemart L, Nelson A, Wong M, Ross JS, Sosman J, Mehnert J, Daniels G, Kendra K, Ali SM, Miller VA, Schrock AB.

Oncologist. 2019 May;24(5):657-663. doi: 10.1634/theoncologist.2018-0271. Epub 2019 Jan 25.

PMID:
30683711
25.

Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart.

Necchi A, Bratslavsky G, Chung J, Millis S, Gay LM, Ali SM, Ross JS.

Oncologist. 2019 Apr;24(4):e142-e145. doi: 10.1634/theoncologist.2018-0430. Epub 2019 Jan 18.

PMID:
30659078
26.

Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.

Day TF, Kallakury BVS, Ross JS, Voronel O, Vaidya S, Sheehan CE, Kasid UN.

Mol Cancer Res. 2019 May;17(5):1207-1219. doi: 10.1158/1541-7786.MCR-18-0731. Epub 2019 Jan 15.

PMID:
30647104
27.

Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia: An Analysis of Within- and Between-Hospital Variation.

Downing NS, Wang C, Gupta A, Wang Y, Nuti SV, Ross JS, Bernheim SM, Lin Z, Normand ST, Krumholz HM.

JAMA Netw Open. 2018 Sep 7;1(5):e182044. doi: 10.1001/jamanetworkopen.2018.2044.

28.

Age of Data at the Time of Publication of Contemporary Clinical Trials.

Welsh J, Lu Y, Dhruva SS, Bikdeli B, Desai NR, Benchetrit L, Zimmerman CO, Mu L, Ross JS, Krumholz HM.

JAMA Netw Open. 2018 Aug 3;1(4):e181065. doi: 10.1001/jamanetworkopen.2018.1065.

29.

Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.

Puthumana J, Miller JE, Kim J, Ross JS.

JAMA Netw Open. 2018 Jun 1;1(2):e180283. doi: 10.1001/jamanetworkopen.2018.0283.

30.

Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes.

Chui PW, Parzynski CS, Ross JS, Desai NR, Gurm HS, Spertus JA, Seto AH, Ho V, Curtis JP.

J Am Heart Assoc. 2019 Jan 22;8(2):e010373. doi: 10.1161/JAHA.118.010373.

31.

Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017.

Vijay A, Ross JS, Shah ND, Jeffery MM, Dhruva SS.

J Gen Intern Med. 2019 Apr;34(4):518-520. doi: 10.1007/s11606-018-4752-8. No abstract available.

PMID:
30623386
32.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S.

Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.

PMID:
30609392
33.

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.

Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R.

Cancer. 2019 Apr 1;125(7):1185-1199. doi: 10.1002/cncr.31921. Epub 2018 Dec 24.

34.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, Chalmers Z, Lotem M, Gibney G, Russell J, Chmielowski B, Ross JS, Stephens PJ, Miller VA, Ali SM.

J Am Acad Dermatol. 2019 Jun;80(6):1780-1782. doi: 10.1016/j.jaad.2018.12.020. Epub 2018 Dec 18. No abstract available.

35.

Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.

Wallach JD, Egilman AC, Ross JS, Woloshin S, Schwartz LM.

J Gen Intern Med. 2019 Apr;34(4):492-495. doi: 10.1007/s11606-018-4779-x. No abstract available.

PMID:
30543020
36.

Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.

Neilsen BK, Sleightholm R, McComb R, Ramkissoon SH, Ross JS, Corona RJ, Miller VA, Cooke M, Aizenberg MR.

J Neurooncol. 2019 Mar;142(1):111-118. doi: 10.1007/s11060-018-03070-2. Epub 2018 Dec 9.

PMID:
30535594
37.

Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism.

Bikdeli B, Wang Y, Jimenez D, Ross JS, Monreal M, Goldhaber SZ, Krumholz HM.

JAMA Intern Med. 2019 Feb 1;179(2):263-265. doi: 10.1001/jamainternmed.2018.5287. No abstract available. Erratum in: JAMA Intern Med. 2019 May 28;:.

PMID:
30535318
38.

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.

Sigal DS, Bhangoo MS, Hermel JA, Pavlick DC, Frampton G, Miller VA, Ross JS, Ali SM.

Oncotarget. 2018 Nov 9;9(88):35809-35812. doi: 10.18632/oncotarget.26260. eCollection 2018 Nov 9.

39.

Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold.

Richman IB, Ross JS.

Ann Intern Med. 2018 Dec 4. doi: 10.7326/M18-3066. [Epub ahead of print] No abstract available.

PMID:
30508426
40.

Overview and experience of the YODA Project with clinical trial data sharing after 5 years.

Ross JS, Waldstreicher J, Bamford S, Berlin JA, Childers K, Desai NR, Gamble G, Gross CP, Kuntz R, Lehman R, Lins P, Morris SA, Ritchie JD, Krumholz HM.

Sci Data. 2018 Nov 27;5:180268. doi: 10.1038/sdata.2018.268.

41.

Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.

Shaw DL, Dhruva SS, Ross JS.

J Manag Care Spec Pharm. 2018 Dec;24(12):1230-1238. doi: 10.18553/jmcp.2018.24.12.1230.

42.

Coordinating Clinical Trials to Confirm Drug Safety and Efficacy-Resolving Uncertainty.

Ross JS.

JAMA Intern Med. 2019 Jan 1;179(1):98. doi: 10.1001/jamainternmed.2018.6037. No abstract available.

PMID:
30477007
43.

Generic Drugs in the United States: Policies to Address Pricing and Competition.

Gupta R, Shah ND, Ross JS.

Clin Pharmacol Ther. 2019 Feb;105(2):329-337. doi: 10.1002/cpt.1314. Epub 2019 Jan 10.

PMID:
30471089
44.

The Early Impact of Medicaid Expansion on Uninsured Patients Undergoing Emergency General Surgery.

Chiu AS, Jean RA, Ross JS, Pei KY.

J Surg Res. 2018 Dec;232:217-226. doi: 10.1016/j.jss.2018.06.037. Epub 2018 Jul 11.

PMID:
30463721
45.

Breakthrough Therapy Designation for New Drugs-Reply.

Puthumana J, Wallach JD, Ross JS.

JAMA. 2018 Nov 20;320(19):2042-2043. doi: 10.1001/jama.2018.15942. No abstract available.

PMID:
30458490
46.

RET rearrangements are actionable alterations in breast cancer.

Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, Schrock AB, Gay LM, Lee E, Dolfi SC, Pham K, Lin S, Yao M, Kulkarni A, DiClemente F, Liu C, Rodriguez-Rodriguez L, Ganesan S, Ross JS, Ali SM, Leyland-Jones B, Hirshfield KM.

Nat Commun. 2018 Nov 16;9(1):4821. doi: 10.1038/s41467-018-07341-4.

47.

Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.

Sokol ES, Feng YX, Jin DX, Basudan A, Lee AV, Atkinson JM, Chen J, Stephens PJ, Frampton GM, Gupta PB, Ross JS, Chung JH, Oesterreich S, Ali SM, Hartmaier RJ.

Ann Oncol. 2019 Jan 1;30(1):115-123. doi: 10.1093/annonc/mdy497.

48.

A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCOR.

Juckett LT, Lin DI, Madison R, Ross JS, Schrock AB, Ali S.

Oncology. 2019;96(2):101-109. doi: 10.1159/000493322. Epub 2018 Oct 31.

PMID:
30380541
49.

Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.

Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM.

Oncologist. 2018 Oct 29. pii: theoncologist.2018-0334. doi: 10.1634/theoncologist.2018-0334. [Epub ahead of print]

PMID:
30373905
50.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.

Schrock AB, Welsh A, Chung JH, Pavlick D, Bernicker EH, Creelan BC, Forcier B, Ross JS, Stephens PJ, Ali SM, Dagogo-Jack I, Shaw AT, Li T, Ou SI, Miller VA.

J Thorac Oncol. 2019 Feb;14(2):255-264. doi: 10.1016/j.jtho.2018.10.008. Epub 2018 Oct 24.

Supplemental Content

Support Center